compounding-guidance

Veterinary drug compounding is legally permissible under AMDUCA when an FDA-approved product is unavailable, clinically unsuitable, or a needed dosage form does not exist. A valid VCPR must be established, and the rationale must be documented in the patient record.

503A compounding pharmacies prepare customized medications for individual patients based on specific prescriptions, whereas 503B facilities are outsourcing manufacturers that produce larger batches. This distinction affects regulatory oversight, sterility requirements, and bulk drug sourcing for veterinary compounding.

To document a compounding prescription decision, record the medical rationale for compounding, confirm that an FDA-approved alternative is unavailable, detail the specific formulation, and maintain the VCPR documentation within the patient record to ensure AMDUCA compliance.

Safety considerations for common veterinary compounded formulations include evaluating drug stability, ensuring proper sterility, and checking excipient safety for specific species, such as avoiding toxic ingredients in transdermal methimazole or flavored suspensions for felines and canines.

The proper workflow for evaluating drug compounding involves assessing the clinical need, performing a risk-benefit analysis, confirming the lack of an FDA-approved product, and completing the required documentation of the prescription decision under AMDUCA guidelines.